Frontage Laboratories (Shanghai) Co., Ltd located at Building 13,Lane 67,Libing Road, Pdudong New Area, Shanghai , has recently completed lab renovation to enhance the comprehensive capabilities in the field of large molecule(LM) bioanalysis in China. Currently Frontage China has expanded LM bioanalysis platforms, such as ELISA, MSD, HTRF, Luminex, Simoa, Ella, flow cytometry, qPCR, and Caris200 automated chemiluminescence immunoassay system. After the renovation, the entire building with approximately 1,600 square meters is devoted to the bioanalysis services of Biologics.
Exton, Pennsylvania, [July 2], 2020 - Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research and development services with presence in both North America and China, today announced Frontage Laboratories, Inc.("Frontage Labs"), a wholly-owned subsidiary of the Group, purchased ACME Bioscience Inc. (“ACME”). According to the agreement, Frontage Labs purchase the entire equity interest in ACME owned by Dr. Jason Zhang and other parties.
Frontage Expands Drug Metabolism & Pharmacokinetic (DMPK) Services by Acquiring Biotranex
Exton, Pennsylvania – Frontage Holdings Corporation ( “Frontage” or “Company”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both North America and China, today announced that Frontage Laboratories, Inc. (“Frontage Labs”), a wholly-owned subsidiary of the Frontage, entered into an equity purchase agreement with third party individuals. According to the agreement, Frontage Labs purchased the entire equity interest in Biotranex, LLC (“Biotranex”).
Revenue grew by 20.8% to US$100.4 million
Adjusted net profit1 grew by 28.7% to US$21.4 million
Future contracted revenue increased by 48.6% to US$109.5 million
The planned expansion of a new facility of 71,000 sq.ft used for expanding CMC2 and bioanalytical services in US is on track
并购助力中国布局CMC业务 / 加速建立药物代谢卓越中心
On March 12, representatives of Frontage Laboratories (Shanghai) Co., Ltd. (“Frontage Shanghai”) and Suzhou Wuzhong Economic and Technological Development Zone Management Committee signed a project cooperation agreement on the leasing of a new research facility. The new laboratory building is located in No. 4 plant of Fumin Phase III High Standard, Wusongjiang Industrial Park, Wuzhong Economic and Technological Development Zone, Suzhou, China, covering an area of more than 215,000 square feet. It will be mainly used for drug metabolism and pharmacokinetic (DMPK) studies and will include an animal facility for non-GLP and GLP PK and toxicology studies.
Frontage is a fast-growing contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services throughout the drug discovery and development process to enable pharmaceutical companies to achieve their drug development goals. The Company benefits greatly from having operations in both the United States and China - the two largest markets for CRO services in the world and is well placed to capture growth opportunities in both markets
Exton, Pennsylvania - Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and product development services with presence in both the United States and China, today announced 11736655 CANADA LTD., an indirectly wholly-owned subsidiary of the Group through Frontage Laboratories, Inc.("Frontage Labs”), entered into a share purchase agreement with J&J Corporate Services, Inc., an independent third party. According to the agreement, 11736655 CANADA LTD. will purchase all of the outstanding shares of BRI Biopharmaceutical Research, Inc. (“BRI”) owned by J&J Corporate Services, Inc.
BRI is a Contract Research Organization (“CRO”) that was established by its current president and founder, Dr. David Kwok, more than 20 years ago in Vancouver, Canada. BRI is engaged in providing science-driven drug discovery and IND/NDA-enabling studies for pharmaceutical and biotechnology companies.
作为CRO，BRI向其客户群提供各种服务，包括但不限于用于测量候选药物，代谢物和生物标记物的生物分析测定，体外药物代谢/ ADME，体内DMPK / ADME，制剂开发，DS / DP稳定性和CMC分析测定，以及抗癌药理学评估。
“Expanding our geographic foothold into Canada and the west coast of North America will allow us to offer our clients proximal access to our DMPK and Bioanalytical Services. It will effectively increase the client base that we currently serves in this specific field, with the potential to increase our revenue generated through these highly specialized services”, said Dr Abdul Mutlib, EVP Frontage DMPK Services, “In addition, the acquisition would extend our current contract research services into human tumor xenograft mouse efficacy models, obesity/diabetes rodent metabolic disease models, and the growing research market in human gut microbiome metabolism and biomarker assays. These services will further complement our current scientific expertise, capabilities and service portfolio to meet the needs of its broad client base.”
“We believe that outsourcing by the pharmaceutical industry is expected to continue to increase in North America and China. upon completion of the acquisition, we will expand our capacity with additional scientists, equipment, and facilities to be used in the provision of existing and novel services to our customers,” said Dr. Song Li, Founder and Honorary Chairman of Frontage, CEO of Frontage Labs, “The combined resources will also enable Frontage to become a global leader in providing DMPK services to our existing and new clients in pharmaceutical and agrochemical industries, and further our goal to establish new centers of excellence in DMPK throughout North America and China.”
Frontage Holdings is a fast-growing contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services throughout the drug discovery and development process to enable pharmaceutical companies to achieve their drug development goals. The Company benefits greatly from having operations in both the United States and China - the two largest markets for CRO services in the world and is well placed to capture growth opportunities in both markets.
The Company believes that a “Two Countries, One System” approach differentiates itself from competitors, as it assures customers the same quality standards in both China and the United States, while also providing the company's customers with a detailed and highly experienced understanding of the regulations and requirements for drug discovery and development in both countries. The Company positions itself as a value-add partner with a focus on solving customers' most significant and complex drug discovery and development challenges. The Company's scientific knowledge base, technical expertise and reputation for high quality services have been integral to its ability to enter into strong long-term strategic relationships and partnerships with key customers.